Author name: Sean Lightheart

Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in […]

Atelerix Limited, which develops and markets innovative solutions for the storage and transport of cells, tissues, and viruses at hypothermic

Following on from LVPEI’s successful proof of concept studies highlighting the successful use of Atelerix’s technology to distribute a limbal-stromal cell therapy throughout

Another fantastic publication highlighting one of the multiple applications Atelerix products have within the scientific research and development industry. Anastassia

The liver microenvironment is proving to be a major obstacle to the success of immunotherapy in solid organ tumours. The

Branco et al. have recently published an excellent paper showing the benefits of Atelerix technology in the preservation of Adipose-Derived

How preservation of urine can impact kidney disease research Background: Each day, 20 people in the UK alone, develop chronic

Pancreatic cancer is one of the most aggressive and lethal solid tumours. Pancreatic ductal adenocarcinoma (PDAC) describes malignancies of the

The EPSRC-SFI Joint Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine (lifETIME CDT) is a partnership

One of the biggest challenges faced by CAR-T Cell manufacturers is the variability among apheresis product, which can negatively impact

The population of haematopoietic stem cells (HSCs) found in our bone marrow are responsible for repopulating the body with all

Peripheral blood mononuclear cells (PBMCs), derived from whole blood or leukapheresis, encompass several major immune cell populations including lymphocytes, monocytes,